Alnylam Pharmaceuticals (NASDAQ:ALNY) Coverage Initiated by Analysts at Redburn Atlantic

Investment analysts at Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) in a note issued to investors on Monday, MarketBeat.com reports. The brokerage set a "buy" rating and a $353.00 price target on the biopharmaceutical company's stock. Redburn Atlantic's price objective would indicate a potential upside of 44.95% from the stock's current price.

A number of other brokerages have also commented on ALNY. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Sanford C. Bernstein reduced their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. HC Wainwright increased their target price on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a "buy" rating in a research note on Monday, February 24th. Finally, Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $316.25.

Remove Ads

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded down $18.64 on Monday, reaching $243.52. 735,603 shares of the company were exchanged, compared to its average volume of 837,082. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The firm has a market capitalization of $31.68 billion, a PE ratio of -112.22 and a beta of 0.30. The stock's fifty day moving average price is $259.89 and its 200 day moving average price is $260.57. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the firm's stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $1,045,822,000. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $577,941,000. Capital Research Global Investors increased its stake in shares of Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after purchasing an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after acquiring an additional 1,245,195 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Alnylam Pharmaceuticals by 496.6% in the fourth quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after acquiring an additional 315,182 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.